Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 1 15Phase 3 14Phase 1/2 9Phase 2/3 5Phase 4 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Cytarabine 11Idarubicin 6fludarabine 5venetoclax 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4posaconazole 3fludarabine phosphate 2Micafungin 2Gemtuzumab 2Filgrastim 2Decitabine 2Daunorubicin 2ruxolitinib 1olutasidenib 1molgramostim 1eltrombopag 1aldesleukin 1aclacinomycins 1Transplantation, Homologous 1Topotecan 1Tobacco Use Cessation Devices 1Thiotepa 1Stem Cell Transplantation 1Safety 1Radiotherapy 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Myeloid, Acute × Gemtuzumab × Clear all
NCT01041040 2013-07-31

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 4 Completed
200 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00304447 2009-07-29

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 4 Completed
30 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡